all the latest information
, arranged by
therapeutic class and intervention. Listed below are recently updated therapeutic classes.
Real-world experience with ruxolitinib in myelofibrosis
Ruxolitinib is a Janus kinase (JAK) 1 and JAK 2 inhibitor approved for primary and secondary intermediate-/high-risk myelofibrosis (MF). The...
Long-term safety analyses of momelotinib in patients with myelofibrosis
Momelotinib is a selective and orally available inhibitor of Janus kinase (JAK) 1, JAK2, and activin A type 1 receptor (ACVR1)...
How can we use the microbiome to improve cancer immunotherapy and alleviate side effect such as graft-versus-host-disease
During the American Association of Cancer Research (AACR) Virtual Annual...
Should ropeginterferon become SoC for all patients with low-risk PV?
During the 25th Congress of the European Hematology Association (EHA), the MPN Hub spoke to Tiziano Barbui, L'ospedale Papa...
Trial update of the MANIFEST study of CPI-0610 in patients with myelofibrosis from EHA 2020
MANIFEST (NCT02158858) is a phase II clinical trial of CPI-0610, a small molecule inhibitor of bromodomain...
MANIFEST study: Does the BET inhibitor CPI-0610 show synergy with ruxolitinib in MF?
Interview with John Mascarenhas, Icahn School of Medicine at Mount Sinai during the 25th Congress of the European...
Why should we target MDM2 with small molecule inhibitor KRT-232 in patients with MF?
During the 25th Congress of the European Hematology Association (EHA), the MPN Hub spoke to Haifa Kathrin Al-Ali,...
What effect does idasanutlin have on TP53-mutated clones in patients with polycythemia vera?
The MPN Hub were pleased to speak to Jean-Jacques Kiladjian during ASH 2019. We asked: What effect does...